Nichi-Iko Resumes Production After Suspension
Firm Had Halted Operations At Namerikawa Facility Due To GMP Issues
Nichi Iko says it has restarted production at its Namerikawa manufacturing plant after the Japanese firm was forced to suspend operations due to alleged GMP violations.
You may also be interested in...
Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.
Japanese generics giant Nichi-Iko had a key manufacturing plant raided by Japanese authorities and regulator the PMDA, per media reports, following the recent suspension of production and sales at the site in the Toyama prefecture.
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.